Urinary symptoms occur in 19% of
human T-cell lymphotropic
virus type 1 (
HTLV-1)-infected
patients who do not fulfill criteria for
HTLV-1-associated myelopathy/
tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP
patients. Few studies have evaluated
therapies for
overactive bladder (OAB) caused by
HTLV-1 infection. This case
report describes the effect of onabotulinum toxin A on the urinary manifestations of three
patients with HAM/TSP and OAB symptoms. The
patients were intravesically administered 200 units of
Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that
Botox® should be a
treatment option for OAB associated with
HTLV-1 infection.